Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: Etiology, pathogenesis and treatment

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 727-749

  Kahan, Barry ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

intracellular activation pathway disruption; mTOR; mTOR inhibitors; sirolimus

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; INTEGRIN; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN KINASE B; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG MONITORING; DRUG TOXICITY; DYSLIPIDEMIA; FIBROSING ALVEOLITIS; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LUNG DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PROPORTIONAL HAZARDS MODEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; WOUND HEALING;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 80051973171     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.579898     Document Type: Review

References (171)

1. Hwang M, Perez CA, Moretti L, Lu B. The mTOR signaling network: Insights from its role during embryonic development. Curr Med Chem 2008;15:1192-208
2. Lisik W. Kahan BD. mTOR inhibitorsmechanism of action explains efficacy and toxicity. Curr Opin Organ Transplant 2004;9:369-82
3. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992;69:1227-36
4. Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell 1996;86:517-20
5. Miyazaki T, Liu ZJ, Kawahara A, et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 1995;81:223-31
6. Hall MN. mTOR-what does it do? Transplant Proc 2008;40:S5-8
7. Ward C, Robertson H, Forrest IA, et al. Hypothesis: Epithelial-to- mesenchymal transition is a common cause of chronic allograft failure. Transplant Proc 2005;37:977-80
8. Saemann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant 2009;9:2655-61
9. Lai JH, Tan TH. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994;269:30077-80
10. Kopf H, de la Rosa GM, Howard OM, Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 2007;7:1819-24
11. Demirkiran A, Hendrikx TK, Baan CC, van der Laan LJ. Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: Does in vitro evidence translate to the clinical setting? Transplantation 2008;85:783-9
12. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998;66:1040-6
13. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202
14. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-80
15. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003;35:37S-51S
16. Kahan BD, Gibbons S, Tejpal N, et al. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991;51:232-9
17. Stepkowski SM, Chen H, Daloze P, Kahan BD. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 1991;51:22-6
18. Kahan BD, Kramer WG. Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther 2001;70:74-81
19. Paczek L, Bechstein W, Wramner L, et al. A phase II; open-label; concentration-controlled, randomized 6-month study of standard-dose tacrolimus + sirolimus + coricosteriods compared to reduced-dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract 170]. Transplantation 2002;74:70
20. Wlodarczyk Z, van Hooff JP, Vanrenterghem Y, et al. Tacrolimus in combination with various dosages of rapamycin in renal recipients: Safety and efficacy of the first 6-month multicenter randomized trial [abstract 554]. Transplantation 2002;74:187
21. Gaber AO, Kahan BD, Van Buren C, et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: Results from an open-label, randomized trial. Transplantation 2008;86:1187-95
22. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-86
23. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation 1997;64:32-5
24. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52
25. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58
26. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004;110:2694-700
27. Montagnino G, Lorca E, Tarantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution: Comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996;10:461-9
28. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4:87-93
29. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience. Transplant Proc 2003;35:25S-34S
30. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/ cyclosporine-treated renal transplant recipients. Transplantation 2005;80:749-58
31. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9
32. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004;18:446-9
33. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9
34. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-94
35. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35
36. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-23
37. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
38. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72
39. Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001;345:93-7
40. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009;20:1149-60
41. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341-50
42. Morris RE, Cao W, Huang X, et al. Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc 1995;27:430-1
43. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000;70:969-75
44. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53
45. Eisen H. Long-term cardiovascular risk in transplantation-insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006;21(Suppl 3):iii9-13
46. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116:2726-33
47. Babu AN, Murakawa T, Thurman JM, et al. Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest 2007;117:3774-85
48. Waller JR, Bicknell GR, Nicholson ML. Sirolimus attenuates the expression of metalloproteinase-2 and -9 and inhibits intimal hyperplasia following balloon angioplasty. Transplant Proc 2002;34:2881-3
49. Bahous SA, Blacher J, Safar ME. Aortic stiffness, kidney disease, and renal transplantation. Curr Hypertens Rep 2009;11:98-103
50. Paoletti E, Amidone M, Cassottana P, et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: A 1-year nonrandomized controlled trial. Am J Kidney Dis 2008;52:324-30
51. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23
52. Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol 2009;54:269-76
53. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-6
54. Seitou T, Murakami M, Komatsubara I, et al. Higher incidence and serum levels of minor cardiac biomarker elevation in sirolimus-eluting stent (Cypher) than bare metal stent implantations. Coron Artery Dis 2008;19:63-9
55. Clavien PA, Camargo CA Jr, Croxford R, et al. Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg 1994;220:109-20
56. Kahan BD, Benavides C, Schoenberg L, et al. Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus. Clin Nephrol 2010;73:344-53
57. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002;43:1170-80
58. Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: Morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004;18:596-604
59. Morales JM, Marcen R, Andres A, et al. Renal transplantation in the modern immunosuppressive era in Spain: Four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl 2008;111:S94-9
60. Stephany BR, Alao B, Budev M, et al. Hyperlipidemia is associated with accelerated chronic kidney disease progression after lung transplantation. Am J Transplant 2007;7:2553-60
61. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-42
62. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model. Am J Transplant 2002;2:551-9
63. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004;4:1308-14
64. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004;78:1332-40
65. Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007;20:27-36
66. Bertoni E, Zanazzi M, Rosati A, et al. Long-term steroid side effects in renal transplantation need a safe steroid withdrawal: A single-center experience. Transplant Proc 1998;30:1303-4
67. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 2001;72:1244-50
68. Salas J, Jansen S, Lopez-Miranda J, et al. The SstI polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats. Am J Clin Nutr 1998;68:396-401
69. Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994;272:1666-71
70. Rodrigo E, Gonzalez-Lamuno D, Ruiz JC, et al. Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. Am J Transplant 2002;2:343-8
71. Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003;3:562-9
72. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010;32:615-25
73. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation 2003;76:375-82
74. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005;5:1748-56
75. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009;9:1115-23
76. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management. Transplantation 2000;69:2085-90
77. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234-48
78. Friend P, Russ G, Oberbauer R, et al. Incidence of anemia in sirolimus-treated renal transplant recipients: The importance of preserving renal function. Transpl Int 2007;20:754-60
79. Afzali B, Al-Khoury S, Shah N, et al. Anemia after renal transplantation. Am J Kidney Dis 2006;48:519-36
80. Chadban SJ, Baines L, Polkinghorne K, et al. Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis 2007;49:301-9
81. Thaunat O, Beaumont C, Chatenoud L, et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005;80:1212-19
82. Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005;79:926-34
83. Augustine JJ, Rodriguez V, Padiyar A, et al. Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium. Transplantation 2008;86:548-53
84. Benavides C, Mahmoud KH, Knight R, et al. Rabbit antithymocyte globulin: A postoperative risk factor for sirolimus-treated renal transplant patients? Transplant Proc 2005;37:822-6
85. Rogers CC, Hanaway M, Alloway RR, et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc 2005;37:795-7
86. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002;74:804-8
87. Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 1999;68:1526-32
88. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008;85:821-6
89. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation 2009;88:1194-202
90. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4:626-35
91. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60
92. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007;7:2522-31
93. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006;6:514-22
94. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74:1070-6
95. Flechner S, Glyda MJ, Steinberg S, et al. for the ORION trial investigators. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: Renal function results from the ORION study [abstract]. Am J Transplant 2007;7:440
96. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007;7:586-94
97. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/ cyclosporine combinations. J Am Soc Nephrol 2001;12:1059-71
98. Cheng CH, Chang HR, Chiang CW, et al. Possible mechanism by which rapamycin increases cyclosporine nephrotoxicity. Transplant Proc 2008;40:2373-5
99. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-706
100. Fuller TF, Freise CE, Serkova N, et al. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003;76:1594-9
101. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51
102. Serr F, Lauer H, Armann B, et al. Sirolimus improves early microcirculation, but impairs regeneration after pancreatic ischemia-reperfusion injury. Am J Transplant 2007;7:48-56
103. Kahan BD, Benavides C, Schoenberg L, et al. Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus. Clin Nephrol 2010;73:344-53
104. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75
105. Hong JC, Kahan BD. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 2001;71:1320-8
106. Weir MR. Optimizing early de novo immunosuppression with sirolimus. Transplant Proc 2008;40:S29-31
107. Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010;23:1084-93
108. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003;3:416-23
109. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004;15:228-33
110. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009;9:1115-23
111. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004;4:953-61
112. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005;18:22-8
113. Pearson TC, Mulgaonkar S, Patel A, et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: Final results of the Spare-the-Nephron (STN) trial. Am J Transplant 2008;8:213
114. Cabezon S, Lage E, Hinojosa R, et al. Sirolimus improves renal function in cardiac transplantation. Transplant Proc 2005;37:1546-7
115. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002;21:540-6
116. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006;82:1153-62
117. Kamar N, Jaafar A, Esposito L, et al. Conversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: Results of a 6-month pilot study. Clin Nephrol 2008;70:118-25
118. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006;21:3252-7
119. Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001;72:438-44
120. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007;7:2522-31
121. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-42
122. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005;20:2517-23
123. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008;8:854-61
124. Ruiz JC, Sanchez A, Rengel M, et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: Preliminary results of the EVERODATA registry. Transplant Proc 2007;39:2157-9
125. Padiyar A, Bodziak KA, Hricik DE, Augustine JJ. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. Am J Transplant 2010;10:310-14
126. Letavernier E, Peraldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80:1198-203
127. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004;4:1869-75
128. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006;21:488-93
129. Faul C, Asanuma K, Yanagida-Asanuma E, et al. Actin up: Regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007;17:428-37
130. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007;2:326-33
131. Daniel C, Ziswiler R, Frey B, et al. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 2000;8:52-62
132. Vogelbacher R, Wittmann S, Braun A, et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007;84:1492-9
133. Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16:2063-72
134. Diekmann F, Rovira J, Carreras J, et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007;18:2653-60
135. Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215-20
136. Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: Incidence, course, and clinical outcomes. Transplantation 2007;84:83-8
137. Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial. Br J Dermatol 2001;145:438-45
138. Ram R, Swarnalatha G, Neela P, Dakshinamurty KV. Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus. Saudi J Kidney Dis Transpl 2008;19:819-20
139. Fricain JC, Cellerie K, Sibaud V, et al. Oral ulcers in kidney allograft recipients treated with sirolimus. Ann Dermatol Venereol 2008;135:737-41
140. Gee I, Trull AK, Charman SC, Alexander GJ. Sirolimus inhibits oxidative burst activity in transplant recipients. Transplantation 2003;76:1766-8
141. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787-90
142. Lindenfeld JA, Simon SF, Zamora MR, et al. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transplant 2005;5:1392-6
143. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002;62:1440-6
144. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-18
145. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000;23:482-90
146. David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007;84:50-5
147. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3:590-8
148. Romagnoli J, Citterio F, Nanni G, et al. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006;38:1034-6
149. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35
150. Krebs M, Brunmair B, Brehm A, et al. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 2007;56:1600-7
151. Cruzado JM. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev (Orlando) 2008;22:73-81
152. Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: The role of immunosuppression. Transplant Proc 2008;40:1885-7
153. Kramer BK, Neumayer HH, Stahl R, et al. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. Transplant Proc 2005;37:1601-4
154. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: What does the current evidence tell us? Transplant Proc 2009;41:S31-8
155. Zick Y. Ser/Thr phosphorylation of IRS proteins: A molecular basis for insulin resistance. Sci STKE 2005;2005:pe4
156. Ghahramani N, Reeves WB, Hollenbeak C. Association between increased body mass index, calcineurin inhibitor use, and renal graft survival. Exp Clin Transplant 2008;6:199-202
157. Briaud I, Dickson LM, Lingohr MK, et al. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 2005;280:2282-93
158. Balcazar N, Sathyamurthy A, Elghazi L, et al. Shiojima I et al. mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. J Biol Chem 2009;284:7832-42
159. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003;52:2731-9
160. Laugharne M, Cross S, Richards S, et al. Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines. Transplantation 2007;83:1635-8
161. Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005;27:733-7
162. Deutsch MA, Kaczmarek I, Huber S, et al. Sirolimus-associated infertility: Case report and literature review of possible mechanisms. Am J Transplant 2007;7:2414-21
163. Bererhi L, Flamant M, Martinez F, et al. Rapamycin-induced oligospermia. Transplantation 2003;76:885-6
164. Kaczmarek I, Groetzner J, Adamidis I, et al. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004;4:1084-8
165. De Miguel MP, Cheng L, Holland EC, et al. Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci USA 2002;99:10458-63
166. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transplant 2000;14:97-109
167. Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005;19:145-52
168. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40:573-85
169. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004;4:2126-31
170. Kovarik JM, Snell GI, Valentine V, et al. Everolimus in pulmonary transplantation: Pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 2006;25:440-6
171. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004;26:499-505